OncoCyte Corp (OCX) Announces Quarterly Earnings Results, Misses Expectations By $0.09 EPS
OncoCyte Corp (AMEX:OCX) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($0.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.09), Bloomberg Earnings reports.
Shares of OncoCyte Corp (OCX) traded down $0.05 during midday trading on Tuesday, hitting $5.90. 9,472 shares of the stock were exchanged, compared to its average volume of 15,981. OncoCyte Corp has a 12-month low of $3.60 and a 12-month high of $7.95.
Several analysts recently commented on OCX shares. ValuEngine downgraded shares of OncoCyte Corp from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Zacks Investment Research raised shares of OncoCyte Corp from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th.
TRADEMARK VIOLATION WARNING: “OncoCyte Corp (OCX) Announces Quarterly Earnings Results, Misses Expectations By $0.09 EPS” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/oncocyte-corp-ocx-announces-quarterly-earnings-results-misses-expectations-by-0-09-eps/1703443.html.
OncoCyte Corp Company Profile
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.